Roche HQ in Basel, Switzerland. (Image credit: Kyle LaHucik/Endpoints News)
As competitors near FDA goalpost, Roche spells out its repeat Alzheimer's setback
Before Roche can turn all eyes on a new version of its more-than-once-failed Alzheimer’s drug gantenerumab, the Big Pharma had to flesh out data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
